MATERIALS & CONSUMABLE GOODSNo sanctions match · screened 20 Nov 2026

Roche

roche.comUpdated 8 Nov 2026

Strategic intent

Roche is a global healthcare company that develops, manufactures, and commercializes innovative biopharmaceutical therapies and in vitro diagnostic solutions to advance personalized medicine.

Key market signals

  • 2026-11: Roche received FDA 510(k) clearance for its cobas eplex respiratory pathogen panel 3 (RP3), expanding its automated diagnostic testing capabilities.
  • 2026-10: Roche signed a licensing agreement with Hansoh Pharmaceutical worth up to $15 billion ($400 million upfront) to co-develop a broad portfolio of antibody-drug conjugates (ADCs).
  • 2026-10: Roche expanded its cardiometabolic and obesity pipeline through a partnership with Rona Therapeutics worth up to $1 billion.
  • 2026-10: Roche prepared for dual US FDA PDUFA dates on November 30 and December 18, 2026, for its breast cancer drug candidate giredestrant, following positive Phase III evERA data.
  • 2026-10: Roche filed fenebrutinib for both relapsing and primary progressive multiple sclerosis in the US under FDA priority review.

Financial health

  • For FY 2025, Roche reported group sales of CHF 61.516 billion (approx. USD 74.1 billion), representing a 7% increase at constant exchange rates (2% in Swiss francs), and a core operating profit of CHF 21.833 billion, up 13% at constant exchange rates (https://www.guidechem.com/news/roche-reports-2025-financial-results-sales-grow-7-to-chf-61-5-billion.html).
  • In the first nine months of 2026, Roche's group sales grew 6% at constant exchange rates, with the company reaffirming its full-year 2026 guidance of mid-single-digit sales growth and high-single-digit core EPS growth (https://allsci.com/news/roche-q3-2026-earnings-call-obesity-dual-agonist-advances-as-giredestrant-filed-in-multiple-sclerosis-under-priority-review).

Impact & compliance

SBTi CommittedSocial ImpactModern Slavery Statement (2026)Scope 3 data: comprehensiveThird-party assured

Forensic audit

  • Aug 2026: The Prescription Medicines Code of Practice Authority (PMCPA) ruled in August 2026 that Roche breached Clause 6.1 …
  • Jun 2025: Roche Diagnostics resolved its Unified Patent Court (UPC) dispute with Tandem Diabetes Care, VitalAire, and other defendants regarding insulin delivery system patents through a settlement in June 2025.
More findings — log in

Proprietary analysis

  • Strategic fit

    AI-calculated strategic alignment score

    Log in to see
  • Cultural fit

    Trust and integrity score

    Log in to see
  • Alignment dimensions

    How this supplier scores against each of your strategic imperatives

    Log in to see
  • Full forensic analysis

    Complete ESG audit, modern slavery risk assessment, labour sentiment analysis, and observed contradictions with evidence trails.

    Log in to see

Want the full analysis?

Strategic and cultural fit scoring, full forensic detail and alignment dimensions, for this supplier and your own.